GlassScriptPhysician profile
Gerardo Hernandez Trillo
NPI 1770521387
$3,559.72
in general payments reported to CMS, 2019-2025
48 companies · $845 in 2025
The $845 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.04 · 2020: $17.71 · 2021: $25.83 · 2022: $362 · 2023: $1,020 · 2024: $1,250 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.37 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $384.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $285.42 | 2022-2025 | |
| Astellas Pharma US INC | $261.95 | 2023-2024 | Padcev, Xospata, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $209.28 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $207.11 | 2023-2025 | Trodelvy |
| Janssen Biotech, INC. | $173.38 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $163.38 | 2023-2024 | Injectafer, Enhertu |
| Celgene Corporation | $161.20 | 2022-2024 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $158.44 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Pharmaessentia USA Corporation | $111.13 | 2022-2024 | Besremi |
| Astrazeneca Pharmaceuticals LP | $109.83 | 2020-2024 | Enhertu, Calquence |
| Abbvie INC. | $93.81 | 2024-2025 | |
| Sobi, INC | $78.47 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $72.75 | 2023-2025 | Givlaari, Oxlumo |
| Array Biopharma INC | $70.10 | 2023-2025 | Lorbrena, Xalkori, Mektovi |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Trillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.